BioLife Solutions

BLFS

Market cap $1.36B

BOTHELL, Wash. , Oct. 7, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools for the cell and gene therapy ("CGT") market, announces the sale of SAVSU Cleo Technologies, LLC.

After multiple acquisitions and significant dilution of shareholders, BioLife shed two freezer businesses which it couldn't get going. Focusing mostly on its core biopreservation media business is putting BLFS on much sounder footing, as it generates the highest margins and the company has a competitive advantage. This is already paying off with cash flow steadily increasing.

The consensus price target hints at a 25.6% upside potential for BioLife Solutions (BLFS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The Zacks Medical products industry sees steady demand, but tariffs & policy headwinds keep growth under pressure in 2025. NVST, BLFS, INFU and MRMD reflect the favorable fundamentals.

BioLife Solutions (BLFS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The mean of analysts' price targets for BioLife Solutions (BLFS) points to a 39.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

BioLife Solutions, Inc. (NASDAQ:BLFS ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Roderick de Greef - CEO & Chairman Troy Wichterman - Chief Financial Officer Conference Call Participants Anna Snopkowski - KeyBanc Capital Markets Inc., Research Division Chad M. Wiatrowski - TD Cowen, Research Division Matthew Jay Stanton - Jefferies LLC, Research Division Yi Chen - H.C.

BioLife Solutions, Inc. (BLFS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.06 per share a year ago.

Cell Processing revenue of $23.0 million, up 28% over Q2 2024 GAAP gross margin of 62%  and non-GAAP adjusted gross margin of 65% GAAP net loss of $15.8 million, inclusive of a non-cash $15.5 million IPR&D expense, and non-GAAP adjusted EBITDA of $6.1 million or 24% of revenue Raises full-year 2025 revenue guidance to $100.0 million - $103.0 million, and full-year 2025 Cell Processing revenue guidance to $91.0 million - $93.0 million Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash.

BOTHELL, Wash. , July 28, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced that as part of a larger round of financing it has purchased $2 million of convertible notes in Pluristyx, Inc. ("Pluristyx"), a Seattle based developer of innovative induced pluripotent stem cell (iSPC) based products for cell therapy developers.